Praxis Medical Insights

Clinical Evaluation

A comprehensive clinical evaluation, including vital signs, pulse oximetry, focused medical history, complete physical examination, and ruling out other etiologies, is recommended by the Centers for Disease Control and Prevention (CDC) for patients with suspected vaping-related lung injury 1
Patients with vaping-related lung injury should be evaluated for oxygen saturation, respiratory distress, and comorbidities to determine if they are candidates for outpatient management, with a saturation of O₂ ≥95% on room air, no respiratory distress, and no comorbidities 1

The American Thoracic Society recommends diagnostic studies, including chest radiography, urinalysis, and testing for influenza and other infectious diseases, for patients with vaping-related lung injury, with consideration of bronchoalveolar lavage or lung biopsy if clinically indicated 1
A diagnostic workup for EVALI should include a detailed history of e-cigarette or vaping product use, chest imaging, exclusion of infectious etiologies, and consideration of bronchoalveolar lavage showing inflammatory cells, lipid-laden macrophages, and possible eosinophilia, as recommended by the CDC 1
Diagnosis of vape-related bronchiolitis obliterans requires a history of e-cigarette or vaping product use, exclusion of infectious etiologies, chest imaging showing characteristic patterns, pulmonary function tests showing fixed airflow obstruction, and in some cases, lung biopsy showing bronchiolitis obliterans 1

The CDC recommends hospitalization for patients with significant respiratory compromise, with consideration of empirical antibiotic use, corticosteroids, and influenza vaccination, and ensuring clinical stability for 24-48 hours before discharge 1
Patients with vaping-related lung injury should be offered cessation services and facilitated connection to support, with consideration of corticosteroid use and careful monitoring for signs of adrenal insufficiency 1
The primary chemical compounds implicated in vape-related bronchiolitis obliterans include diacetyl (2,3-butanedione), 2,3-pentanedione, and other α-dicarbonyl compounds, which can cause direct airway epithelial necrosis, damage to biological molecules, disruption of protein homeostasis, and airway fibrosis resembling bronchiolitis obliterans 1

The American College of Chest Physicians recommends follow-up care, including evaluation of vital signs, physical examination, and laboratory tests, within 48 hours of discharge, with continued education on vaping-related lung injury and adherence to medication regimens 1
Patients with vaping-related lung injury should be scheduled for follow-up with a pulmonologist within 2-4 weeks, with evaluation of pulmonary function and radiographic findings, and consideration of additional testing 1-2 months after discharge 1
Incomplete medication counseling, such as failing to provide thorough counseling to patients on corticosteroid tapers for EVALI, can lead to rehospitalization, and patients should have follow-up within 48 hours of hospital discharge, and schedule follow-up with pulmonology within 2-4 weeks for those with significant respiratory symptoms 1

The CDC strongly recommends complete cessation of all e-cigarette and vaping product use to prevent worsening of respiratory symptoms and progression to serious conditions like EVALI 1
Nicotine Replacement Therapy (NRT) may be effective in helping individuals quit vaping, with combination NRT (nicotine patch plus gum or nasal spray) considered a viable option, and higher-dose nicotine patch therapy (>25 mg/day) may provide incremental benefit for prolonged therapy 2
The "5 As" approach, which includes asking about tobacco/vaping use, advising to quit, assessing willingness to quit, assisting in quitting, and arranging follow-up and support, can be used to support vaping cessation 3

The CDC reported 2,409 hospitalized cases of E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI) by December 2019, highlighting the severity of vaping-related health issues 1
Patients with EVALI may present with pleuritic chest pain, progressive dyspnea, cough, systemic symptoms, and respiratory failure in severe cases, particularly if they develop pleural effusions, which occur in approximately 50% of patients 1, 4
Early follow-up (within 48 hours) is crucial to prevent readmissions, with at least one-quarter of readmissions and deaths occurring within 2 days of discharge 1
Hospital pharmacist counseling before discharge improves medication adherence and reduces readmission, especially for patients with tapering corticosteroid regimens 1